A detailed history of Walleye Capital LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 20,071 shares of NUVL stock, worth $1.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,071
Holding current value
$1.68 Million
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$67.44 - $112.17 $1.35 Million - $2.25 Million
20,071 New
20,071 $2.05 Million
Q1 2024

May 15, 2024

SELL
$72.35 - $88.99 $1.96 Million - $2.42 Million
-27,159 Reduced 43.26%
35,623 $2.67 Million
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $1.22 Million - $2.31 Million
28,803 Added 84.77%
62,782 $4.62 Million
Q3 2023

Nov 21, 2023

SELL
$39.12 - $49.85 $178,661 - $227,664
-4,567 Reduced 11.85%
33,979 $1.56 Million
Q3 2023

Nov 14, 2023

BUY
$39.12 - $49.85 $1.51 Million - $1.92 Million
38,546 New
38,546 $1.77 Million

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.6B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.